Cargando…

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy

Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the pauci...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoriadou, S, Clubbe, R, Garcez, T, Huissoon, A, Grosse-Kreul, D, Jolles, S, Henderson, K, Edmonds, J, Lowe, D, Bethune, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585546/
https://www.ncbi.nlm.nih.gov/pubmed/35924867
http://dx.doi.org/10.1093/cei/uxac070
_version_ 1784813516307300352
author Grigoriadou, S
Clubbe, R
Garcez, T
Huissoon, A
Grosse-Kreul, D
Jolles, S
Henderson, K
Edmonds, J
Lowe, D
Bethune, C
author_facet Grigoriadou, S
Clubbe, R
Garcez, T
Huissoon, A
Grosse-Kreul, D
Jolles, S
Henderson, K
Edmonds, J
Lowe, D
Bethune, C
author_sort Grigoriadou, S
collection PubMed
description Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.
format Online
Article
Text
id pubmed-9585546
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95855462022-10-24 British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy Grigoriadou, S Clubbe, R Garcez, T Huissoon, A Grosse-Kreul, D Jolles, S Henderson, K Edmonds, J Lowe, D Bethune, C Clin Exp Immunol Editors’ Choice Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care. Oxford University Press 2022-08-04 /pmc/articles/PMC9585546/ /pubmed/35924867 http://dx.doi.org/10.1093/cei/uxac070 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Editors’ Choice
Grigoriadou, S
Clubbe, R
Garcez, T
Huissoon, A
Grosse-Kreul, D
Jolles, S
Henderson, K
Edmonds, J
Lowe, D
Bethune, C
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title_full British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title_fullStr British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title_full_unstemmed British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title_short British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
title_sort british society for immunology and united kingdom primary immunodeficiency network (ukpin) consensus guideline for the management of immunoglobulin replacement therapy
topic Editors’ Choice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585546/
https://www.ncbi.nlm.nih.gov/pubmed/35924867
http://dx.doi.org/10.1093/cei/uxac070
work_keys_str_mv AT grigoriadous britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT clubber britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT garcezt britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT huissoona britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT grossekreuld britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT jolless britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT hendersonk britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT edmondsj britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT lowed britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy
AT bethunec britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy